Taysha Gene Therapies TSHA Stock
Taysha Gene Therapies Price Chart
Taysha Gene Therapies TSHA Financial and Trading Overview
| Taysha Gene Therapies stock price | 2.5 USD |
| Previous Close | 0.74 USD |
| Open | 0.77 USD |
| Bid | 0 USD x 1300 |
| Ask | 0 USD x 1000 |
| Day's Range | 0.74 - 0.79 USD |
| 52 Week Range | 0.61 - 5.09 USD |
| Volume | 153.61K USD |
| Avg. Volume | 373.19K USD |
| Market Cap | 49.1M USD |
| Beta (5Y Monthly) | 1.172867 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.96 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.13 USD |
TSHA Valuation Measures
| Enterprise Value | 44.6M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.75 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 6.811408 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 6.187 |
| Enterprise Value/EBITDA | -0.509 |
Trading Information
Taysha Gene Therapies Stock Price History
| Beta (5Y Monthly) | 1.172867 |
| 52-Week Change | -72.77% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.09 USD |
| 52 Week Low | 0.61 USD |
| 50-Day Moving Average | 0.73 USD |
| 200-Day Moving Average | 1.54 USD |
TSHA Share Statistics
| Avg. Volume (3 month) | 373.19K USD |
| Avg. Daily Volume (10-Days) | 190.98K USD |
| Shares Outstanding | 64.18M |
| Float | 38.78M |
| Short Ratio | 4.8 |
| % Held by Insiders | 39.61% |
| % Held by Institutions | 31.46% |
| Shares Short | 1.23M |
| Short % of Float | 2.91% |
| Short % of Shares Outstanding | 1.90% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1233.83% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -41.54% |
| Return on Equity (ttm) | -745.27% |
Income Statement
| Revenue (ttm) | 7.21M USD |
| Revenue Per Share (ttm) | 0.14 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 2.5M USD |
| EBITDA | -87692000 USD |
| Net Income Avi to Common (ttm) | -133319000 USD |
| Diluted EPS (ttm) | -2.44 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 63.43M USD |
| Total Cash Per Share (mrq) | 0.99 USD |
| Total Debt (mrq) | 60.85M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.329 |
| Book Value Per Share (mrq) | -0.235 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -67636000 USD |
| Levered Free Cash Flow (ttm) | -54692876 USD |
Profile of Taysha Gene Therapies
| Country | United States |
| State | TX |
| City | Dallas |
| Address | 3000 Pegasus Park Drive |
| ZIP | 75247 |
| Phone | 214 612 0000 |
| Website | https://www.tayshagtx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 65 |
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Q&A For Taysha Gene Therapies Stock
What is a current TSHA stock price?
Taysha Gene Therapies TSHA stock price today per share is 2.5 USD.
How to purchase Taysha Gene Therapies stock?
You can buy TSHA shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Taysha Gene Therapies?
The stock symbol or ticker of Taysha Gene Therapies is TSHA.
Which industry does the Taysha Gene Therapies company belong to?
The Taysha Gene Therapies industry is Biotechnology.
How many shares does Taysha Gene Therapies have in circulation?
The max supply of Taysha Gene Therapies shares is 220.37M.
What is Taysha Gene Therapies Price to Earnings Ratio (PE Ratio)?
Taysha Gene Therapies PE Ratio is now.
What was Taysha Gene Therapies earnings per share over the trailing 12 months (TTM)?
Taysha Gene Therapies EPS is -0.96 USD over the trailing 12 months.
Which sector does the Taysha Gene Therapies company belong to?
The Taysha Gene Therapies sector is Healthcare.
Taysha Gene Therapies TSHA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}